1492 related articles for article (PubMed ID: 21646062)
1. Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry.
Abdel-Wahab M; Nienaber CA; Mostafa AE; Sabin G; Tebbe U; Hochadel M; Senges J; Akin I; Kuck KH; Hamm C; Richardt G;
EuroIntervention; 2011 Jun; 7(2):201-8. PubMed ID: 21646062
[TBL] [Abstract][Full Text] [Related]
2. Treatment of coronary bifurcation lesions with drug-eluting stents: insights from the first phase of the prospective multicenter german drug-eluting stent registry.
Abdel-Wahab M; Nienaber CA; Mostafa AE; Ferenc M; Silber S; Sabin G; Tebbe U; Akin I; Hochadel M; Senges J; Kuck KH; Richardt G;
J Interv Cardiol; 2012 Aug; 25(4):344-52. PubMed ID: 22409587
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
[TBL] [Abstract][Full Text] [Related]
4. Outcomes after differential use of drug-eluting stents in diabetic patients: 1-year results from the DES.DE (Drug-Eluting Stent.DEutschland) registry.
Akin I; Bufe A; Eckardt L; Reinecke H; Richardt G; Kuck KH; Senges J; Schneider S; Nienaber CA;
Catheter Cardiovasc Interv; 2010 Jul; 76(1):50-7. PubMed ID: 20578192
[TBL] [Abstract][Full Text] [Related]
5. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
[TBL] [Abstract][Full Text] [Related]
6. Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention.
Takasawa Y; Iijima R; Shiba M; Nakamura M; Sugi K
J Cardiol; 2010 May; 55(3):391-6. PubMed ID: 20350511
[TBL] [Abstract][Full Text] [Related]
7. Two-year clinical outcomes of paclitaxel-eluting stents for in-stent restenosis in patients from the ARRIVE programme.
Lee MS; Yang T; Lasala JM; Cox DA; Bowman TS; Starzyk RM; Dawkins KD
EuroIntervention; 2011 Jul; 7(3):314-22. PubMed ID: 21729833
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
[TBL] [Abstract][Full Text] [Related]
9. Are drug-eluting stents indicated in large coronary arteries? Insights from a multi-centre percutaneous coronary intervention registry.
Yan BP; Ajani AE; New G; Duffy SJ; Farouque O; Shaw J; Sebastian M; Lew R; Brennan A; Andrianopoulos N; Reid C; Clark DJ;
Int J Cardiol; 2008 Nov; 130(3):374-9. PubMed ID: 18706719
[TBL] [Abstract][Full Text] [Related]
10. Everolimus-eluting versus paclitaxel-eluting stents for treatment of bare metal stent restenosis.
Almalla M; Schröder JW; Pross V; Stegemann E; Marx N; Hoffmann R
Am J Cardiol; 2011 Aug; 108(4):518-22. PubMed ID: 21624553
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome after management of unprotected left main in-stent restenosis after bare metal or drug-eluting stents.
Chen SL; Xu B; Mintz G; Ye F; Zhang JJ; Kan J; Sun XW; Zhang AP; Chen JG; Qian J; Kwan TW
Chin Med J (Engl); 2010 Apr; 123(7):794-9. PubMed ID: 20497666
[TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
13. Clinical and procedural predictors of suboptimal outcome after the treatment of drug-eluting stent restenosis in the unprotected distal left main stem: the Milan and New-Tokyo (MITO) registry.
Takagi K; Ielasi A; Shannon J; Latib A; Godino C; Davidavicius G; Mussardo M; Ferrarello S; Figini F; Carlino M; Montorfano M; Chieffo A; Nakamura S; Colombo A
Circ Cardiovasc Interv; 2012 Aug; 5(4):491-8. PubMed ID: 22851528
[TBL] [Abstract][Full Text] [Related]
14. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents.
Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome after drug eluting stenting in patients with ST-segment elevation myocardial infarction: data from the REAL registry.
Campo G; Saia F; Percoco G; Manari A; Santarelli A; Vignali L; Varani E; Benassi A; Sangiorgio P; Tarantino F; Magnavacchi P; De Palma R; Guastaroba P; Marzocchi A
Int J Cardiol; 2010 Apr; 140(2):154-60. PubMed ID: 19056134
[TBL] [Abstract][Full Text] [Related]
16. Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation.
Jeong YH; Hong MK; Lee CW; Park DW; Kim YH; Kim JJ; Park SW; Park SJ
Int J Cardiol; 2008 Mar; 125(1):36-40. PubMed ID: 17521753
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of optimal treatment strategies for in-stent restenosis after drug-eluting stent implantation.
Song HG; Park DW; Kim YH; Ahn JM; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Han S; Seong IW; Lee NH; Lee BK; Lee K; Lee SW; Nah DY; Park SJ
J Am Coll Cardiol; 2012 Mar; 59(12):1093-100. PubMed ID: 22421303
[TBL] [Abstract][Full Text] [Related]
19. [Safety and current indications during "real life" use of sirolimus-eluting coronary stents in Germany. Results from the prospective multicenter German Cypher Registry].
Zahn R; Hamm CW; Zeymer U; Schneider S; Nienaber CA; Richardt G; Kelm M; Levenson B; Bonzel T; Tebbe U; Schöbel WA; Sabin G; Senges J;
Herz; 2004 Mar; 29(2):181-6. PubMed ID: 15057439
[TBL] [Abstract][Full Text] [Related]
20. Contemporary treatment of in-stent restenosis and the incidence of recurrent in-stent restenosis in the era of drug-eluting stents.
Ajani AE; Yan BP; Clark DJ; Eccleston D; Walton A; Lew R; Meehan A; Brennan A; Reid C; Duffy SJ;
Heart Lung Circ; 2007 Aug; 16(4):269-73. PubMed ID: 17419097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
